1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 29 FEBRUARY 2016

Cancer Drug News 29 FEBRUARY 2016

  • March 2016
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Portrazza To Be Modest Contributor To Lilly Revenue Maintenance
Industry Brief - Gazyva FDA-Approved For Previously Treated Follicular Lymphoma Population
Industry Brief - Ixazomib Granted Orphan Drug Designation In Japan
Industry Brief - CHMP Recommends Acalabrutinib As Orphan Medicinal Drug For Lymphomas
Industry Brief - Asterias Concludes End-of-Phase II Meeting With FDA For AST-VAC1
Industry Brief - Peregrine Terminates Bavituximab Phase III SUNRISE Trial
Industry Brief - First Patients Treated In Tedopi Phase III Advanced NSCLC Trial
Industry Brief - FDA Accepts sNDA For Xtandi In MCRPCA
Industry Brief - FDA Approves Novartis' Afinitor For Non-Functional NETs
Industry Brief - CHMP Recommends Opdivo And Lonsurf Approvals
Industry Trend Analysis - Unmet Medical Need From Pancreatic Cancer To Grow
Industry Trend Analysis - Growing Cancer Burden To Attract Drugmakers
Industry Trend Analysis - Myriad's Diversification Drive Builds Strong Portfolio
Industry Brief - OSE Pharma/Effimune Enter Merger Agreement To Form Immunotherapy Company

Table Of Contents

Cancer Drug News 29 FEBRUARY 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hodgkin’s Lymphoma in 17 Major Markets Hodgkin’s Lymphoma (HL) is a cancer (also known as Hodgkin Disease, Hodgkin Lymphoma o ...

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market  Forecast-2023

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Small lymphocytic lymphoma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.